{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:50:35Z","timestamp":1784152235438,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"kom op tegen kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The outcome of patients with muscle-invasive bladder cancer (MIBC) remains poor, despite aggressive treatments. Inadequate primary staging, classically performed by computed tomography (CT)-imaging, could lead to inappropriate treatment and might contribute to these poor results. Although not (yet) adapted by international guidelines, several reports have indicated the superiority of <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose-positron emission tomography-CT (<jats:sup>18<\/jats:sup>F-FDG-PET-CT) compared to CT in the detection of lymph node and distant metastases. Thereby the presence of extra-vesical disease on <jats:sup>18<\/jats:sup>F-FDG-PET-CT has been correlated with a worse overall survival. This supports the hypothesis that <jats:sup>18<\/jats:sup>F-FDG-PET-CT is useful in stratifying MIBC patients and that adapting the treatment plan accordingly might result in improved outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>EFFORT-MIBC is a multicentric prospective phase II trial aiming to include 156 patients. Eligible patients are patients with histopathology-proven MIBC or\u2009\u2265\u2009T3 on conventional imaging treated with MIBC radical treatment, without extra-pelvic metastases on conventional imaging (thoracic CT and abdominopelvic CT\/ magnetic resonance imaging (MRI)). All patients will undergo radical local therapy and if eligible neo-adjuvant chemotherapy. An <jats:sup>18<\/jats:sup>F-FDG-PET-CT will be performed in addition to and at the timing of the conventional imaging. In case of presence of extra-pelvic metastasis on <jats:sup>18<\/jats:sup>F-FDG-PET-CT, appropriate intensification of treatment with metastasis-directed therapy (MDT) (in case of \u22643 metastases) or systemic immunotherapy (&gt;\u20093 metastases) will be provided. The primary outcome is the 2-year overall survival rate. Secondary endpoints are progression-free survival, distant metastasis-free survival, disease-specific survival and quality of life. Furthermore, the added diagnostic value of <jats:sup>18<\/jats:sup>F-FDG-PET-CT compared to conventional imaging will be evaluated and biomarkers in tumor specimen, urine and blood will be correlated with primary and secondary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is a prospective phase II trial evaluating the impact of <jats:sup>18<\/jats:sup>F-FDG-PET-CT in stratifying patients with primary MIBC and tailoring the treatment accordingly. We hypothesize that the information on the pelvic nodes can be used to guide local treatment and that the presence of extra-pelvic metastases enables MDT or necessitates the early initiation of immunotherapy leading to an improved outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The Ethics Committee of the Ghent University Hospital (BC-07456) approved this study on 11\/5\/2020. The trial was registered on <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> (NCT04724928) on 21\/1\/2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08861-x","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T17:49:23Z","timestamp":1634579363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-1394","authenticated-orcid":false,"given":"Flor","family":"Verghote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlien","family":"Berghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Villeirs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"De Visschere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathia","family":"De Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"De Maeseneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Decaestecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"6","key":"8861_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8861_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tau.2018.09.11","volume":"8","author":"MGK Cumberbatch","year":"2019","unstructured":"Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5\u201311. https:\/\/doi.org\/10.21037\/tau.2018.09.11.","journal-title":"Transl Androl Urol"},{"issue":"9","key":"8861_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3390\/jcm8091459","volume":"8","author":"F Janisch","year":"2019","unstructured":"Janisch F, Yu H, Vetterlein MW, Dahlem R, Engel O, Fisch M, et al. Do younger patients with muscle-invasive bladder Cancer have better outcomes? J Clin Med. 2019;8(9):1459. https:\/\/doi.org\/10.3390\/jcm8091459.","journal-title":"J Clin Med"},{"issue":"9","key":"8861_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"issue":"20","key":"8861_CR5","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity score analysis of radical cystectomy versus bladder-sparing Trimodal therapy in the setting of a multidisciplinary bladder Cancer clinic. J Clin Oncol. 2017;35(20):2299\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.69.2327.","journal-title":"J Clin Oncol"},{"key":"8861_CR6","unstructured":"EAU: Guidelines Muscle-invasive and Metastatic Bladder Cancer. https:\/\/uroweb.org (2021). Accessed 16 Jun 2021."},{"issue":"1","key":"8861_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40336-020-00397-7","volume":"9","author":"V Fonteyne","year":"2021","unstructured":"Fonteyne V, De Man K, Decaestecker K, De Visschere P, Dirix P, De Meerleer G, et al. PET\u2013CT for staging patients with muscle invasive bladder cancer: is it more than just a fancy tool? Clin Transl Imaging. 2021;9(1):83\u201394. https:\/\/doi.org\/10.1007\/s40336-020-00397-7.","journal-title":"Clin Transl Imaging"},{"key":"8861_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bju.12138","volume":"111","author":"LS Mertens","year":"2013","unstructured":"Mertens LS, Mir C, Scott AM, Lee ST, Bruining A, Vegt E, et al. PET\/CT predicts mortality in muscle invasive bladder cancer. BJU Int. 2013;111:71.","journal-title":"BJU Int"},{"issue":"8","key":"8861_CR9","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/0218492315596463","volume":"23","author":"Y Shimada","year":"2015","unstructured":"Shimada Y, Saji H, Kakihana M, Kajiwara N, Ohira T, Ikeda N. Survival outcomes for oligometastasis in resected non-small cell lung cancer. Asian Cardiovasc Thorac Ann. 2015;23(8):937\u201344. https:\/\/doi.org\/10.1177\/0218492315596463.","journal-title":"Asian Cardiovasc Thorac Ann"},{"issue":"1","key":"8861_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/1471-2407-14-671","volume":"14","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed therapy for OligoMetastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14(1):671. https:\/\/doi.org\/10.1186\/1471-2407-14-671.","journal-title":"BMC Cancer"},{"issue":"5","key":"8861_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","volume":"67","author":"P Ost","year":"2015","unstructured":"Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.004.","journal-title":"Eur Urol"},{"issue":"2","key":"8861_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyz152","volume":"50","author":"T Abe","year":"2020","unstructured":"Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, et al. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol. 2020;50(2):206\u201313. https:\/\/doi.org\/10.1093\/jjco\/hyz152.","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"8861_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"8861_CR14","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.","author":"NIH National Cancer Institute","year":"2017","unstructured":"NIH National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). https:\/\/ctep.cancer.gov. Accessed 1 Jun 2021."},{"issue":"5","key":"8861_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"AN Fau","year":"1993","unstructured":"Aaronson Nk Fau - Ahmedzai S, Ahmedzai S Fau - Bergman B, Bergman B Fau - Bullinger M, Bullinger M Fau - Cull A, Cull A Fau - Duez NJ, Duez Nj Fau - Filiberti A, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365\u2013376, DOI: https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"8861_CR16","unstructured":"EORTC Quality of Life: QLQ-BLM30 muscle invasive bladder cancer. https:\/\/qol.eortc.org\/questionnaire\/qlq-blm30. Accessed 10 Jun 2021."},{"issue":"2","key":"8861_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P Fau - Bogaerts J, Bogaerts J Fau - Schwartz LH, Schwartz Lh Fau - Sargent D, Sargent D Fau - Ford R, Ford R Fau - Dancey J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228\u2013247, DOI: https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"2","key":"8861_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R Fau - Thielke R, Thielke R Fau - Payne J, Payne J Fau - Gonzalez N, Gonzalez N Fau - Conde JG, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377\u2013381, DOI: https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08861-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08861-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T17:51:17Z","timestamp":1634579477000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08861-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8861"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08861-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the Ethics Committee of the Ghent University Hospital on 11\/5\/2020 (BC-07456). Any significant change or addition to the protocol will only be made in a written protocol amendment that is approved by the Ethics Committee. All patients will give their written informed consent before inclusion. This will be obtained after a clear and thorough discussion between the patient and the consenting physician.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VF has received grant funding from Ipsen and has consulted for Ipsen and Janssen, all unrelated to this research project. PO has received grants from Ferring Pharmaceuticals, Merck, Varian and Bayer, has consulted for Ferring Pharmaceuticals, Bayer, Janssen, Curium and Novartis, all unrelated to this research project. VPC has consulted for Astellas, unrelated to this project. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1113"}}